• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

    9/22/25 9:03:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email

    Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.

    MIAMI BEACH, Fla., Sept. 22, 2025 /PRNewswire/ -- Evolus, Inc. (NASDAQ:EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami Beach's premier Avabello Aesthetics, as lead consultant for the national launch of their revolutionary Evolysse™ filler line. This partnership comes as Evolus introduces the first major technological breakthrough in hyaluronic acid dermal fillers in a decade, with Dr. Eskenazi providing critical expertise to support aesthetic providers nationwide.

    Avabello Aesthetics

    As lead consultant, Dr. Eskenazi will leverage his extensive experience in the injectable space and deep knowledge of facial anatomy to assist aesthetic providers should questions arise during treatment with the new Evolysse™ products. While not specifically mandated by the FDA or any regulatory agency, this collaboration showcases Evolus' proactive commitment to patient safety and provider support during the launch of their groundbreaking filler technology.

    The FDA recently approved Evolysse™ Form and Evolysse™ Smooth, marking Evolus' entry into the U.S. hyaluronic acid dermal filler market. The revolutionary fillers utilize innovative Cold-X™ technology that preserves the natural structure of the hyaluronic acid molecule for longer-lasting, natural-looking results.

    "I'm honored to partner with Evolus in bringing this innovative technology to practitioners across the country," said Dr. Eskenazi. "My role is to provide real-world expertise and guidance to ensure providers feel confident and supported when using these advanced fillers. This collaboration reflects Evolus' genuine commitment to patient safety and demonstrates their dedication to excellence in aesthetic medicine."

    Evolus specifically selected Dr. Eskenazi based on his distinguished track record as an aesthetic educator, expert injector, and recognized authority in facial aesthetics. Dr. Eskenazi brings over eight years of private practice experience and completed his plastic surgery training at the world-renowned Cleveland Clinic Foundation, gaining extensive expertise in both aesthetic and reconstructive procedures.

    The partnership positions Dr. Eskenazi as a key resource for aesthetic providers nationwide who may encounter questions or challenges during Evolysse™ treatments. His expertise will be available to support the medical community as they integrate this breakthrough technology into their practices.

    Avabello stands apart as one of the few medical spas in Miami Beach overseen by a board-certified plastic surgeon, ensuring that every treatment is performed with the highest level of medical expertise. This fundamental understanding of aesthetics brings unparalleled safety and effectiveness to the services offered at the practice.

    The Evolysse™ line represents a significant advancement in dermal filler technology, with clinical studies providing compelling evidence around their safety and efficacy. The commercial launch of Evolysse™ Form and Evolysse™ Smooth in 2025 will be followed by Evolysse™ Sculpt in 2026, and Evolysse™ Lips in 2027.

    More About Avabello Aesthetics

    Avabello is a premier luxury cosmetic wellness destination that seamlessly blends high-end aesthetic treatments with the highest standards of medical expertise. Located in Miami Beach, the practice offers a holistic approach to beauty and wellness, featuring cutting-edge non-invasive and minimally invasive treatments delivered in a sophisticated, spa-like environment.

    Distinguished by its direct oversight from renowned board-certified plastic surgeon Benjamin Eskenazi, MD, FACS, Avabello elevates every treatment with medical precision, personalized care, and a commitment to enhancing natural beauty. Dr. Eskenazi is a graduate of the prestigious Emory University School of Medicine who initially pursued heart surgery before discovering his passion for plastic surgery during his residency at UT Southwestern.

    Dr. Eskenazi is dual board-certified by the American Board of Surgery and the American Board of Plastic Surgery, and serves as a featured speaker at national aesthetic medicine conferences.  He is a Fellow of the American College of Surgeons, and a Member of the American Society of Plastic Surgeons and American Society of Aesthetic Plastic Surgeons. His dedication to innovation, precision, and patient satisfaction has earned him recognition as one of the country's leading plastic surgeons.

    Media Contact

    Isabella Franco

    Avabello Aesthetics

    (305) 798-4656

    [email protected]

    https://www.avabello.com

    Dr. Benjamin Eskenazi

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/top-miami-plastic-surgeon-dr-benjamin-eskenazi-named-lead-consultant-for-evolus-evolysse-filler-launch-302562162.html

    SOURCE Avabello Aesthetics

    Get the next $EOLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    8/6/2025Buy → Hold
    Needham
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

    Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line. MIAMI BEACH, Fla., Sept. 22, 2025 /PRNewswire/ -- Evolus, Inc. (NASDAQ:EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami Beach's premier Avabello Aesthetics, as lead consultant for the national launch of their revolutionary Evolysse™ filler line. This partnership comes as Evolus introduces the first major techn

    9/22/25 9:03:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company, and 143,403 shares of Evolus common stock and 104,603 RSUs of the company's common stock to Tatjana Mitchell, the company's new Chief Financial Officer. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan as an inducement m

    9/12/25 5:30:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolus downgraded by Needham

    Needham downgraded Evolus from Buy to Hold

    8/6/25 7:20:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Evolus with a new price target

    BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus upgraded by Barclays with a new price target

    Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

    1/29/24 7:09:38 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stewart Brady bought $204,486 worth of shares (30,000 units at $6.82), increasing direct ownership by 51% to 88,629 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/18/25 4:28:22 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    6/10/25 5:04:47 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    SEC Filings

    View All

    Evolus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Evolus, Inc. (0001570562) (Filer)

    9/8/25 8:32:35 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Evolus Inc.

    SCHEDULE 13G - Evolus, Inc. (0001570562) (Subject)

    8/18/25 12:11:38 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

    SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

    8/14/25 4:23:29 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Marketing Officer Yamagishi-Dressler Tomoko sold $42,972 worth of shares (5,722 units at $7.51), decreasing direct ownership by 6% to 89,949 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/26/25 6:26:31 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Stewart Brady bought $204,486 worth of shares (30,000 units at $6.82), increasing direct ownership by 51% to 88,629 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    8/18/25 4:28:22 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Moatazedi David sold $1,283,195 worth of shares (127,905 units at $10.03), decreasing direct ownership by 26% to 364,927 units (SEC Form 4)

    4 - Evolus, Inc. (0001570562) (Issuer)

    6/16/25 4:42:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    View All

    Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companies in retail, consumer, data, and technology-driven businesses. She brings a proven track record of driving revenue growth, scaling organizations, and leading transformation efforts through disciplined financial management and strategic execution. Most recently, Ms. Mitchell served as Senior Vice President of Corporate Finance at Experian

    9/8/25 8:30:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

    1/4/24 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:50:28 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/14/24 4:00:06 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolus Inc.

    SC 13G/A - Evolus, Inc. (0001570562) (Subject)

    11/13/24 5:38:05 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EOLS
    Financials

    Live finance-specific insights

    View All

    Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in International Markets Evolysse™ Delivered $9.7 Million in Revenue for Q2 2025, Marking the Strongest Filler Launch Quarter in Over a Decade and Providing a Solid Foundation for Second Half Growth Expects to Achieve Meaningful Profitability1 in Q4 2025 and Annual Profitability1 Beginning in 2026; Strategic Cost Structure Optimization Expected to Yield At Least $25 Million in Non-GAAP Operating Expense Savings for 2025 Resets 2025 Net Revenue Guidance to $295 Million to $305 Mi

    8/5/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus to Report Second Quarter Financial Results on August 5, 2025

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic r

    7/22/25 8:05:00 AM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolus Reports First Quarter 2025 Results

    Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

    5/7/25 4:05:00 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care